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Abstract 
The metabolic transition from anaerobic glycolysis and fatty acid β-oxidation to glycolysis coupled 
to oxidative phosphorylation is a key process for the transition of quiescent neural stem cells to 
proliferative neural progenitor cells. However, a full characterization of the metabolic shift and the 
involvement of mitochondria occurring during the last step of neurogenesis, from neuroblasts to 
neurons maturation, is still elusive. Here, we describe a model of neuroblasts, Neuro2a cells, with 
impaired differentiation capacity due to mitochondrial dysfunction. Using a detailed biochemical 
characterization consisting of steady state metabolomics and metabolic flux analysis, we found 
increased fatty acid β-oxidation as peculiar feature of neuroblasts with altered mitochondria. The 
consequent metabolic switch favored neuroblast proliferation at the expense of neuron maturation. 
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Abbreviations 
[U-13Cx] Uniformly labeled 13Carbon, x = labeled carbon number 
36B4 Ribosomal protein, large, P0 
ADP Adenosine diphosphate 
AMP Adenosine phosphate 
ATP Adenosine triphosphate 
Atp5a1 
ATP synthase, H+ transporting, mitochondrial F1 complex, alpha 
subunit 1 
AUC Area under the curve 
BCA Bicinchoninic acid 
BLT-1 Block of lipid transport 1 
BSA Bovine serum albumin 
Carnitine-C0  DL-Carnitine 
Carnitine-C10 Decanoyl-L-carnitine 
Carnitine-C12 Dodecanoyl-L-carnitine 
Carnitine-C14 Tetradecanoyl-L-carnitine 
Carnitine-C16:0 Hexadecanoyl-L-carnitine 
Carnitine-C16:1 Hexadecenoyl-L-carnitine 
Carnitine-C18:0 Octadecanoyl-L-carnitine 
Carnitine-C18:1 Octadecenoyl-L-carnitine 
Carnitine-C2 Acetyl-L-carnitine 
Carnitine-C3 Propionyl-L-carnitine 
Carnitine-C4 Butyryl-L-carnitine 
Carnitine-C5 Valeryl-L-carnitine 
Carnitine-C6 Hexanoyl-L-carnitine 
Carnitine-C8 Octanoyl-L-carnitine 
Carnitine-C9 Nonayl-L-carnitine 
CCCP Carbonyl cyanide m-chlorophenyl hydrazone 
CoA Coenzyme A 
Cpt1a Carnitine palmitoyl-transferase 
Cs Citrate synthase 
DMEM Dulbecco’s modified Eagle’s medium 
E4P Erythrose-4-phosphate 
EtBr Ethidium bromide 
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ETC Electron transport chain 
F1,6BP Fructose-1,6-bisphosphate 
FADH2 Flavin adenine dinucleotide reduced 
FBS Fetal bovine serum 
FDR False discovery rate 
G6P/F6P Glucose/Fructose-6-phosphate 
GAP/DHAP Glyceraldehyde-3-phosphate/Dihydroxyacetone phosphate 
H2DCFDA 2′,7′-Dichlorodihydrofluorescein diacetate 
HPLC High-performance liquid chromatography 
Hsp90 Heat-shock protein 90 
HTS High-throughput screening 
Idh3 NAD+-dependent isocitrate dehydrogenase 3 
LC-MS/MS Liquid chromatography tandem mass spectrometry 
MID Mass isotopomer distribution 
MRM Multiple reaction monitoring 
mt-COI Cytochrome C oxidase subunit 1 
mtDNA mitochondrial DNA  
mt-ND1 
Mitochondrially Encoded NADH:Ubiquinone Oxidoreductase Core 
Subunit 1 
N2a Neuro2a cells 
NAA N-acetylaspartate 
NAD+ nicotinamide adenine dinucleotide 
NADH nicotinamide adenine dinucleotide reduced 
NADP+ Nicotinamide adenine dinucleotide phosphate 
NADPH Nicotinamide adenine dinucleotide phosphate reduced 
Ndufb8 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8 
NPCs Neural progenitor cells 
NSCs Neural stem cells 
OAA Oxaloacetate 
OCR Oxygen consumption rate 
Oligo Oligomycin 
Oxphos Oxidative phosphorylation 
PBS Phosphate buffer saline 
PEP Phosphoenolpyruvate 
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PITC Phenylisothiocyanate 
Ribu/Xilu/Ribo5P Ribulose/Xylulose/Ribose-5-phosphate 
RIPA buffer Radio immunoprecipitation assay buffer 
ROS Reactive oxygen species 
RT Room temperature 
Sdhb Succinate dehydrogenase subunit b 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SR-B1 Scavenger receptor class B type 1 
TBS Tris buffered saline 
TCA tricarboxylic acid 
Tfam Transcription factor A mitochondria 
TMPD N,N,N′,N′-tetramethyl-p-phenylenediamine 
Tubb3 Tubulin Beta 3 Class III 
Tuj1 Neuron-specific class III beta-tubulin 
Uqcrc2 Ubiquinol-Cytochrome C Reductase Core Protein 2 
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Introduction 
Mitochondria are ubiquitous and multi-functional organelles involved in several cellular processes, 
such as energy production and synthesis of metabolites regulating vital functions. During the 
developmental process, cells change their metabolic states to support cellular differentiation [1,2]. 
Therefore, cells need a substantial amount of energy to cope with the newly established homeostasis 
that they have acquired during cellular differentiation. In other words, cells shift from glycolysis to 
oxidative phosphorylation (Oxphos), thus mitochondrial function and biogenesis are boosted during 
the cellular differentiation process [1,2]. Several lines of evidences demonstrate that interference with 
mitochondrial biogenesis during differentiation slows down or even blocks the differentiation process 
[1–3]. 
The neurogenic process – known as neurogenesis – in mammals is accomplished by neural 
stem cells (NSCs) at the prenatal phase and is maintained during postnatal stage, even though the 
presence of NSCs in adult brain is still matter of debate [4–6]. Mitochondria play key role in NSCs 
during development and adulthood to maintain proper neurological functions [7]. As mentioned 
above, NSCs, as well as other progenitor cells, during the generation of the neuronal lineage switch 
their metabolism from primarily anaerobic glycolysis and fatty acid catabolism to glycolysis that 
requires actively functional mitochondria [7]. In addition, glutamine metabolism is increased during 
of neuron differentiation [8]. Neuronal cell fate becomes more apparent at the neural progenitor cells 
(NPCs) stage. Neurons differentiated from NPCs undergo morphological changes via axonal and 
dendritic arborization, resulting in a change in cell polarity. Newborn neurons migrate to their 
destination and make connections with pre-existing neurons by forming synapses and integrating into 
an established neuronal circuit. In addition, during the transition from NSCs to NPCs, mitochondria 
change their shape from elongated to fragmented, a process required for cell cycle exit to support 
cellular differentiation [7–9]. Finally, NPCs give rise to committed neuroblasts, the last differentiation 
step before the mature neurons.  
 Several efforts have been done to disentangle the role of mitochondria and metabolism in 
quiescent and proliferative NSCs [10], or during the transition from NSCs to NPCs [7,9,11]. 
Nevertheless, little is currently known about metabolic changes and thus the role of mitochondria 
during the maturation phase from neuroblasts to neurons.  
Here, we took advantage of a widely used model of neuroblasts, such as Neuro2a cells (N2a), 
with impaired differentiation capacity due to chemically induced mitochondrial dysfunction. 
Biochemical characterization of these cells revealed increased fatty acid β-oxidation as peculiar 
feature of neuroblasts with altered mitochondria, that favored neuroblast proliferation to the detriment 
of neuron maturation. Our data highlighted that proper mitochondrial activity and metabolism in 
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neuroblasts is necessary in the final transition to neurons, as it occurs in the preceding stages of 
neurogenesis. 
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Materials and methods 
Cell lines 
Neuro2a cells (ATCC, CCL-131) were maintained in growth medium (high-glucose DMEM) 
supplemented with 10% fetal bovine serum (FBS) (v/v) (Euroclone), 1% glutamine (v/v) (Thermo 
Fisher Scientific), 1% penicillin/streptomycin (v/v) (Thermo Fisher Scientific) and in 37°C, 5% CO2 
and 90% humidified atmosphere. N2a were differentiated by growing cells to 50% of confluence and 
switching growth medium to differentiation medium (1% FBS (v/v), 1% glutamine (v/v), 1% 
penicillin/streptomycin (v/v). Neuro2a cells were treated for 30 days with ethidium bromide 
100ng/ml. Complete media was supplemented with 400μM uridine (U3750, Sigma Aldrich) and 
1mM pyruvate (11360070, Thermo Scientific). 
 
Cell proliferation assay 
N2a cells were seeded at a density of 5 x 104 per cm2 in black 96-well plates and incubated in complete 
medium. 24, 48 and 72 hours later, cells were washed in PBS and exposed to 32μM of Hoechst 
(33258, Life Technologies) in DMEM for 45 minutes at 37° C in the dark. Cells were washed again 
in PBS and fluorescence (wavelength of 445nm) was revealed by using EnVision plate reader (2100, 
Perkin Elmer). 
 
Cell viability assay 
N2a cells were seeded at a density of 5 x 104 per cm2 in black 96-well plates and incubated in complete 
medium. 24 and 48 hours later, cells were washed in PBS and exposed to 5mg/ml of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent in PBS for 30 minutes at 37° 
C. Cells were washed again in PBS, lysed in 100μl of DMSO and shacked for 5 min. Absorbance 
(wavelength of 590nm) was revealed by using EnVision plate reader (2100, Perkin Elmer). 
 
ROS level quantification 
N2a cells were seeded at a density of 5 x 104 per cm2 in black 96-well plates and incubated in complete 
medium. 24 hours later, cells were washed in PBS and exposed to 10μM of H2DCFDA (D399, Life 
Technologies) and 32μM of Hoechst (33258, Life Technologies) in DMEM for 45 minutes at 37° C 
in the dark. Cells were washed again in PBS and fluorescence (wavelength of 529nm for H2DCFDA 
and 445nm for Hoechst, respectively) was revealed by using EnVision plate reader (2100, Perkin 
Elmer). 
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Neurite quantification 
N2a were fixed in formalin for 10 minutes and then stained for 20 min with the following solution: 
0.02% Coomassie brilliant blue R-250 (w/v) in methanol: acetic acid: water, 46.5:7:46.5 (v/v/v) [12]. 
Cells were then extensively rinsed in sterile water and images were acquired in brightfield. Cell 
number was quantified by ImageJ software while neurite number, neurite length and neurite contacts 
were quantified by NeuronJ software. 
 
Mitochondrial DNA (mtDNA) quantity and relative transcription quantification 
Total DNA and mtDNA were isolated using genomic DNA from tissues kit (Macherey-Nagel, 
740952.250). Briefly, samples were scraped from dishes and spun at 2,000g for 3 min at RT. Cells 
were then resuspended in lysis buffer and DNA was isolated following manufacturer’s instructions. 
Samples were eluted in 60µl of DNase and RNase free water and quantified by UV spectrophotometry 
(NanoDrop 1000 Spectrophotometer, Thermo Fisher Scientific). Mitochondrial DNA content was 
evaluated by assessing mt-ND1 and 36B4 content as mitochondrial and nuclear-encoded genes, 
respectively. mt-DNA transcription was evaluated by normalizing mitochondrially encoded RNA on 
mtDNA content. Primers and probes were obtained from Eurofins Genomics MWG-Operon and are 
available upon request. 
 
Western blot 
Protein relative quantification analyses were carried out by separating cell lysates on SDS-PAGE. 
Cells were rinsed in ice-cold PBS, centrifuged and resuspended in RIPA buffer without SDS. Protein 
concentration was measured using BCA method (EMP014500, Euroclone). Proper protein amount 
was then resuspended in 1:1 v/v SDS-sample buffer and loaded on SDS-PAGE. After gel run, proteins 
were transferred to a nitrocellulose membrane and blocked in 5% bovine serum albumin (BSA, 
A8022, Sigma Aldrich) for 1 hour at RT. Membranes were then incubated O/N at 4°C with primary 
antibodies, previously resuspended in 0,1% TBS-Tween20 and 3% BSA. After extensive washes, 
membranes were incubated with HRP-conjugated secondary antibodies for 1.5 hour at RT. After 
washing, membranes were finally incubated with ECL substrate for bands detection. Primary and 
secondary antibodies were diluted as follows: OXPHOS cocktail 1:2000 (Abcam, ab110413), Tuj1 
(D71G9, Cell Signaling), Hsp90 1:1000 (Santa Cruz Biotech., sc-7947). Blots were quantified by 
ImageJ software. 
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Oxygen consumption measurements 
Oxygen consumption rate (OCR) analysis on whole cells was performed by using a Clark type oxygen 
electrode (Hansatech, DW1 electrode chamber). N2a cells were rinsed in pre-warmed PBS (37°C) 
and suspended in coupled respiration buffer (2% free fatty acids-BSA, 1mM Na-pyruvate, 25 mM D-
glucose, 40 ng/ml digitonin) or electron flow buffer (2% free fatty acids -BSA, 10mM Na-pyruvate, 
2mM malate, 4µM carbonyl cyanide m-chlorophenyl hydrazine (CCCP), digitonin 40ng/ml). 
Samples were then transferred to the electrode chamber for the oxygen consumption rate 
measurement. After measuring basal respiration, uncoupled and maximal respiration were evaluated 
by adding 5μM oligomycin and 5μM CCCP, respectively. Complex I, II and IV activities were 
evaluated through the electron flow protocol. Once transferred into the chamber, CI activity was 
evaluated. After 5µM rotenone and 2.5mM succinate addition, we assessed complex II activity. We 
then added 50µM antimycin A and 12.5mM/0.5mM Ascorbate/N,N,N',N'-tetramethyl-p-
phenylenediamine (TMPD) to measure complex IV activity. Samples values were normalized on total 
protein content. 
 
Steady state metabolomics and metabolite flux analysis 
Cells were grown in 6-well plates, harvested in ice-cold PBS and centrifuged at 2,000g for 3 min at 
4°C. Pellets were then resuspended in 250µl methanol/acetonitrile 1:1 containing [U-13C6]-Glucose 
(Sigma Aldrich, 389374) and [U-13C5]-Glutamine 1ng/µl (Sigma Aldrich, 605166) as internal 
standards and spun at 20,000g for 5 min at 4°C. Supernatant were then passed through a regenerated 
cellulose filter, dried and resuspended in 100µl of MeOH for subsequent analysis. Amino acids 
quantification was performed through previous derivatization. Briefly, 50µl of 5% phenyl 
isothiocyanate (PITC) in 31.5% EtOH and 31.5% pyridine in water were added to 10µl of each 
sample. Mixtures were then incubated with PITC solution for 20 min at RT, dried under N2 flow and 
suspended in 100µl of 5mM ammonium acetate in MeOH/H2O 1:1. Metabolomic data were 
performed on an API-4000 triple quadrupole mass spectrometer (AB Sciex) coupled with a HPLC 
system (Agilent) and CTC PAL HTS autosampler (PAL System) and on SCIEX Triple Quad™ 3500 
LC-MS/MS. The identity of all metabolites was confirmed using pure standards. Quantification of 
different metabolites was performed with a liquid chromatography/tandem mass spectrometry (LC-
MS/MS) method using a C18 column (Biocrates) for amino acids, Pursuit XRs Ultra 2.8 Diphenyl 
(Varian) for acyl-carnitine and cyano-phase LUNA column (50mm x 4.6mm, 5µm; Phenomenex) for 
metabolites, respectively. Methanolic samples were analyzed by a 10 min and 3 min run in positive 
(amino acids and acyl-carnitine) and 5 min run in negative (all other metabolites) ion mode with a 35 
multiple reaction monitoring (MRM) transition in positive ion mode and 30 MRM transition in 
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negative ion mode, respectively. The mobile phases for positive ion mode analysis (amino acids) 
were phase A: 0.2% formic acid in water and phase B: 0.2% formic acid in acetonitrile. The gradient 
was T0 100%A, T5.5min. 5%A, T7min 100%A with a flow rate of 500µl/min. The mobile phase for acyl-
carnitine analysis was 0.1% formic acid in MeOH in isocratic condition with a flow rate of 300µl/min. 
The mobile phase for negative ion mode analysis (all other metabolites) was phase A: Water and B: 
2 mM ammonium acetate in MeOH. The gradient was 90% B for all the analysis with a flow rate of 
500µl/min. MultiQuant™ software (version 3.0.2) was used for data analysis and peak review of 
chromatograms. Metabolomic data were normalized by defining !"# (relative metabolite area) as: !"#= $"∑ "&'()  
where xn represents the peak areas of metabolite n for samples a, b,…, z and ∑ *+",-  represents the 
sum of peak areas of metabolite n for samples a, b,…, z.  
Relative metabolite area (!"#) was then divided by the sum of relative metabolite areas analyzed in 
each sample to obtain relative metabolite abundance (m), as: .-#= /'0∑ -')(1  
where ∑ 2"-,3  represents the sum of relative metabolite areas 1, 2, …, n for sample a. Internal 
standards were used to control instrument sensitivity. 
For metabolic tracing analyses, N2a cells were exposed for 24 hours to [U-13C6]-Glucose 1mM or 
[U-13C5]-Glutamine 2mM or [U-13C16]-Palmitate 100μM (Sigma Aldrich, 605573). Metabolite 
isotopomers quantification was performed as described above after setting 139 new MRMs. Heatmap 
and principal component analysis (PCA) were obtained by interrogating MetaboAnalyst 4.0 webtool 
(https://www.metaboanalyst.ca/) [13]. 
 
Statistical analysis 
Statistical analyses were performed with Student’s t-test or two-way ANOVA followed by Sidak’s 
multiple comparison test using GraphPad Prism (version 6.0) and MetaboAnalyst 4.0 [13] where 
indicated. Grubbs’test (https://www.graphpad.com/quickcalcs/Grubbs1.cfm) and principal 
component analyses (a feature of MetaboAnalyst 4.0 https://www.metaboanalyst.ca/) 
were used to identify eventual outliers, however no outliers were detected. n (reported in each figure 
legends) represents number of independent cell culture preparations. 
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Results 
Generation of a model of dysfunctional mitochondria in neuroblasts 
In order to unravel the role of mitochondria and metabolism in Neuro2a (N2a) cell 
differentiation, we used a gene independent approach to alter mitochondrial function. Therefore, N2a 
cells were treated for 30 days with a low dose of ethidium bromide (EtBr, 100ng/ml). Surprisingly, 
undifferentiated EtBr treated N2a cells showed increased mitochondrial DNA (mtDNA) levels (Fig. 
1a). Given the polycistronic nature of mitochondrial RNA, the analysis of a gene encoded by 
mitochondrial genome is indicative of mitochondrial RNA abundance. Therefore, we normalized 
mtND1 steady state mRNA with mtDNA levels as a proxy of mitochondrial genome transcription. 
As reported in Fig. 1a, data suggest that EtBr treatment, despite increasing mtDNA content, reduced 
its transcription. This result was further corroborated by decreased levels of mtDNA-encoded COI (a 
subunit of electron transport chain (ETC) complex IV), and nuclear encoded subunit Sdhb (a subunit 
of ETC complex II) and Ndub8 (a subunit of ETC complex I) (Fig. 1b). In line with these findings, 
basal, uncoupled and maximal uncoupled respiration were significantly reduced in N2a EtBr-treated 
cells, as well as complex I, II and IV activities (Fig. 1c and d), while total reactive oxygen species 
(ROS) levels were unchanged (Fig.1e). 
We next decided to demonstrate that chemically-induced Oxphos deficiency impacts 
significantly the biology of N2a cells. Based on the observation that cells exhibiting defective Oxphos 
are less capable to grow in galactose rich medium [14], we evaluated cell viability in control and 
EtBr-treated cells in the presence of 4.5 g/L galactose. In line with the fact that, in the absence of 
glucose, the ability to use galactose as energy substrate relies on Oxphos-derived ATP, EtBr-treated 
cells showed reduced cell growth compared to wild type (Fig. 1f). Notably, cell proliferation in 
glucose-containing media was comparable between wild type and EtBr-treated cells, suggesting that 
glycolysis may compensate the Oxphos deficiency (Fig. 1g). Collectively, these findings showed that 
a low dose of EtBr treatment is sufficient to alter mitochondrial function and metabolism in N2a cells. 
 
Phenotypic effects of Oxphos deficiency on N2a differentiation 
To evaluate the effects of EtBr on N2a cell differentiation, we assessed cellular morphology 
and the expression of differentiation markers. From a morphological point of view, N2a wild type 
cells properly differentiated as evidenced by neurite network formation (Fig. 2a and Supplementary 
Fig. 1a) and cell cycle exit, sustained by reduced cell number compared to proliferating neuroblasts 
(Supplementary Fig. 1b). On the other hand, N2a EtBr-treated cells displayed reduced neurite 
number, length and contacts (Fig. 2a and b; Supplementary Fig. 1a). Furthermore, mRNA (Tubb3) 
and protein levels of Tuj1 were significantly decreased in EtBr-treated cells (Fig. 2c and d).  
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Basal, uncoupled and maximal uncoupled respiration and ETC complex activities in wild type 
and EtBr differentiated cells suggested that the differentiation impairment was due to Oxphos 
deficiency. As shown in fig. 2e, EtBr treated N2a still retained defects in oxygen consumption rates 
under basal conditions and also displayed a reduction of ETC complex I activity. ETC complex II 
and IV activities showed a trend to increase, probably to compensate the respiratory defects in 
complex I. These results were further sustained by Oxphos protein levels, indeed Ndufb8 (ETC 
complex I subunit) was reduced while Sdhb (ETC complex II subunit) and Atp5a1 (a subunit of 
ATPase complex) were increased (Fig 2f and g). Together these data demonstrated that EtBr 
treatment blunted N2a differentiation process as well as mitochondrial function. 
 
Mitochondrial dysfunctional N2a neuroblasts show impaired metabolic profile 
 On the basis of the data previously reported and the tight relationship between mitochondria, 
metabolism and cell differentiation, we analyzed the intracellular metabolite levels. To capture early 
changes that may act as drivers of the observed phenotype, we conducted steady state metabolomics 
in undifferentiated wild type and Oxphos deficient N2a. Principal component analysis significantly 
discriminated the wild type cell population from that of N2a treated with EtBr (Supplementary Fig. 
2). Steady state measurements indicated that among 58 metabolites detected, 18 were significantly 
changed (Fold change > 1.5; False Discovery Rate (FDR) < 0.1) in EtBr treated neuroblasts compared 
to wild type cells (Fig. 3a). Specifically, 9 metabolites such as arginine, aspartate, glutamine, 
glyceraldehyde-3-phosphate/dihydroxyacetone phosphate, phosphoenolpyruvate, pyruvate, 
ribulose/xylulose/ribose-5-phosphate, fumarate and malate were decreased in N2a EtBr treated cells 
(Fig 3b). On the other hand, 9 metabolites such as ADP, NADP+, tryptophan, acetyl-L-carnitine 
(carnitine-C2), octanoyl-L-carnitine (carnitine-C8), tetradecanoyl-L-carnitine (carnitine-C14), 
hexadecanoyl-L-carnitine (carnitine-C16:0) and hexadecenoyl-L-carnitine (carnitine-C16:1) and 
octadecenoyl-L-carnitine (carnitine-C18:1) were increased in EtBr treated N2a undifferentiated cells 
compared to wild type (Fig. 3c). Moreover, carnitine-C16:0 + octadecanoyl-L-carnitine (carnitine-
C18:0)/free carnitine (carnitine-C0) ratio, as measure of the activity of carnitine palmitoyl-transferase 
1a (Cpt1a), was increased in EtBr N2a, as well as carnitine-C2/carnitine-C0 ratio, indicating higher 
β-oxidation of fatty acids (Supplementary Fig. 3a and b). Overall, these data suggest that neuroblasts 
with dysfunctional mitochondria exhibit impaired glycolysis and amino acid metabolism. The 
increased levels of several carnitines strongly suggest a preferential use of fatty acids. 
 
14 
 
Neuroblasts with dysfunctional mitochondria use fatty acids oxidation to sustain cell 
proliferation 
To evaluate the dependence on extracellular lipids of both wild type and EtBr N2a cells, we 
used scavenger receptor, class B, type I (SR-BI) lipid transporter antagonist BLT-1 (block of lipid 
transport 1) and measured cell proliferation. As shown in Fig. 4a both wild type and EtBr cells showed 
decreased growth compared to vehicle-treated cells, suggesting that lipid uptake is requested to 
maintain the proliferation rate. Next, in order to discriminate if fatty acid contribution to cell 
proliferation is also mediated by their oxidation in mitochondria, we challenged cells with palmitate 
in the absence or presence of carnitine. The enzyme Ctp1a, localized on the outer mitochondrial 
membrane, leverages carnitine to transfer fatty acids into mitochondria, representing the rate limiting 
step of fatty acid oxidation. In the absence of carnitine, palmitate was uncapable to sustain cell 
survival (Fig. 4b), instead carnitine promoted fatty acid β-oxidation and sustained cell viability in 
EtBr-treated N2a cells (Fig. 4c). These data were further sustained by significantly reduced cell 
viability in EtBr-treated cells exposed to etomoxir, the chemical inhibitor of Cpt1a (Fig. 4d). 
Furthermore, EtBr-treated N2a cultured in presence of carnitine and palmitate showed increased ROS 
levels (Fig. 4e). This is probably due to the impaired Oxphos of EtBr-treated N2a that inefficiently 
cope with the overload of reducing cofactors (NADH and FADH2) deriving from fatty acid oxidation. 
Taken together, these data demonstrated that EtBr-treated N2a cells rewired their metabolism 
and showed greater dependence on palmitate oxidation compared to wild type cells to sustain cell 
proliferation. 
 
Neuroblasts with dysfunctional mitochondria exhibit altered tricarboxylic acid (TCA) cycle and 
utilization of energy substrates 
 To gain more detailed insight into metabolism of EtBr-treated neuroblasts, we cultured cells 
in the presence of 1mM [U‐13C6]glucose, 1mM [U‐13C5]glutamine, or 100μM [U‐13C16]palmitate for 
24 hours and analyzed the labeling of TCA cycle intermediates in each condition. As shown in Fig. 
5a, EtBr-treated N2a cells incorporated comparable amount of carbons from labeled glucose into M2 
acetyl-CoA of wild type cells, suggesting a comparable rate of glucose oxidation through glycolysis. 
The incorporation of one molecule of labeled acetyl-CoA into citrate (first entry of glucose-derived 
carbons in the TCA cycle, carbons 1 and 2) was similar in both EtBr and wild type cells suggesting 
that citrate synthase (Cs) activity was not affected. In contrast, M2 citrate labeled in carbons 3 and 4, 
indicative of a single TCA cycle round was downregulated in EtBr treated cells (Fig. 5b). On the 
other hand, M4 citrate (carbons 1, 2, 3 and 4), originated by the incorporation of two molecules of 
M2 acetyl-CoA, was increased in EtBr treated cells (Fig. 5b). These data suggest that in Oxphos 
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deficient N2a Cs activity is not affected, while the defects may reside in other downstream reactions 
of the TCA cycle. This concept is further sustained considering the incorporation of [U‐13C6]glucose-
derived carbons in a-ketoglutarate (aKG), an intermediate formed downstream of citrate. Indeed, M2 
aKG (labeled in 1 and 2 deriving from citrate M2 labeled in 1 and 2) and M2 aKG (labeled carbons 
3 and 6 from multiple TCA cycles) were decreased in N2a treated with EtBr (Fig. 5c), as well as M3 
aKG produced from M4 citrate after NAD+-dependent isocitrate dehydrogenase 3 (Idh3) activity 
(Fig. 5c). Furthermore, no major differences were detected considering the incorporation of [U‐
13C6]glucose-derived carbons in oxaloacetate (OAA) (Fig. 5d). These data indicate a major defect in 
Idh3 activity. 
 Glutamine can be utilized in the mitochondria by oxidative metabolism and/or can be routed 
to the cytoplasmic reductive pathway. When undifferentiated wild type and EtBr-treated N2a cells 
where cultured in the presence of [U‐13C5]glutamine, the levels of M2 acetyl-CoA were comparable 
between the two experimental conditions (Fig. 5e). Interestingly, the M2 citrate (labeled in carbons 1 
and 2) produced by the glutamine reductive pathway and Cs activity was reduced in N2a treated with 
EtBr (Fig. 5f). Similarly, M2 citrate (labeled in positions 3 and 5) derived by glutamine reductive 
pathway and pyruvate carboxylase activity was significantly decreased in Oxphos deficient cells (Fig. 
5f). Conversely, M5 citrate produced by reductive pathway (labeled in carbons 1, 2, 3, 5 and 6), as 
well as M4, M5 (labeled in positions 1, 2, 3, 4 and 5) and M6 citrate forms originated from glutamine 
oxidative metabolism were unchanged (Fig. 5f). These results are further substantiated by decreased 
levels of M2 (derived from citrate labeled in positions 1 and 2) and M3 (produced by citrate M4) 
aKG detected in N2a with dysfunctional mitochondria (Fig. 5g). Levels of M5 aKG were comparable 
between experimental groups, indicating that glutamine conversion to aKG is not affected by EtBr 
treatment (Fig 5g). In addition, M3 OAA levels, only ascribable to reductive glutamine metabolism, 
were blunted in N2a cells treated with EtBr (Fig. 5h). Altogether, the analysis of isotopomers from 
glutamine labeling suggests a major defect in the reductive pathway and further confirms impaired 
Idh3 activity. 
 Next, we investigated fatty acid utilization by means of [U‐13C16]palmitate tracing. In this 
experimental setting, we found that the incorporation of [U‐13C16]palmitate-derived carbons in M2 
acetyl-CoA was increased in EtBr-treated N2a cells compared to wild type (Fig. 5i). Furthermore, 
M2 (labeled in carbons 3 and 4) and M4 citrate, as well as M2 (from citrate labeled in positions 1 and 
2) and M3 aKG, generated from several rounds of the TCA cycle, were increased in N2a with 
dysfunctional mitochondria (Fig. 5j and 5k). Also, M2 OAA (derived from the first TCA round) 
showed a trend to increase, while M3 OAA (derived from multiple TCA rounds) was decreased 
compared to wild type control (Fig. 5l). These observations are consistent with the increased β-
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oxidation as indicated by steady-state metabolomics and reduced TCA cycle flux as indicated tracing 
analyses. 
To gain a complete overview on the fluxes of different metabolic substrates into TCA, we 
calculated the contribution of each labeled substrate to citrate abundance. As reported in Fig. 5m and 
based on the above described data, N2a EtBr-treated cells showed i) significantly less glutamine flux 
in the reductive pathway, ii) accumulation of glucose-derived carbons in citrate due to reduced Idh3 
activity and iii) increased fatty acid oxidation. Collectively, these data demonstrated that neuroblasts 
with dysfunctional mitochondria shift their metabolism towards more fatty acid oxidation compared 
to wild type cells (Fig 5n). 
 As reported above, EtBr-treated cells proliferated to the same extent of N2a wild type (Fig. 
1f). In addition, we showed that in contrast to wild type cells, N2a with defective mitochondrial 
function exhibited increased fatty acid oxidation and higher capacity to grow in the presence of 
palmitate (Fig 3 and 4). We next sought to ascertain the fate of fatty acid-derived carbons. Indeed, 
several TCA cycle intermediates are substrates for amino acid synthesis, that in turn are key 
molecules required for cell viability. Notably, we found increased incorporation of [U‐
13C16]palmitate-derived carbons into M2 aspartate (derived from M2 OAA labeled in 1 and 2, Fig. 
5l), M2 glutamate and M2 proline (from M2 aKG labeled in 1 and 2, Fig. 5k) in EtBr-treated N2a 
(Fig. 6a). Instead, M2 glutamine (from M2 glutamate) was unchanged between groups (Fig. 6b), 
while M3 glutamine (from M3 glutamate, undetectable levels) was decreased in N2a treated with 
EtBr compared to wild type cells (Fig. 6c). Considering metabolic labeling with [U‐13C6]glucose, our 
analyses revealed unchanged levels of M2 aspartate between the experimental conditions (Fig.6d), 
while M2 glutamate, M2 proline, M2 and M3 glutamine were decreased compared to wild type 
control (Fig.6e). Furthermore, we observed decreased M2 aspartate, unchanged levels of M4 aspartate 
(Fig.6f), reduced M2 and M3 glutamate, and unchanged levels of M5 glutamate originating from [U‐
13C5]glutamine (Fig.6g) in EtBr-treated N2a compared to wild type cells. Moreover, we found 
decreased levels of M2 proline (Fig.6h) and M5 glutamine from the same labeled substrate in N2a 
cells with dysfunctional mitochondria (Fig.6i). Finally, we observed increased glucose derived M2 
alanine, produced by pyruvate transamination in the cytoplasm (Supplementary Fig.4a), and no 
changes in other non-essential amino acids labeling (Supplementary Fig. 4b, c and d). Taken together, 
these data corroborate the metabolic re-channeling of glucose and palmitate derived carbons in EtBr-
treated N2a cells to maintain key amino acid biosynthesis required for cell proliferation (Fig.6j).  
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Discussion 
 Neurogenesis is a biological process beginning from neural stem cells to mature neuron 
formation. This process is necessary for the development of the nervous system to ensure proper 
cognitive functions, such as behavior, mood, memory [1,15,16], and brain plasticity [17–21]. 
During neuronal devolvement, cells experience metabolic shift from mainly anaerobic 
glycolysis and fatty acid oxidation to higher glucose oxidative and glutamine metabolism [1,2]. 
Neurons consumes a substantial amount of glucose and glutamine to accomplish intra and 
extracellular signaling, dendritic and axonal transport, to re-establish action potential, and recycling 
of neurotransmitters after depolarization [8]. In the last few years, also lipid metabolism has been 
shown to contribute to neurogenesis, indeed Knobloch and colleagues demonstrated that lipogenesis 
is critical for neural differentiation [22], while fatty acid oxidation is fundamental for the proliferation 
of neural stem/progenitor cell pool [9,10,23]. However, the biochemical mechanisms leading to 
decreased fatty acid oxidation during neural differentiation are not yet fully understood. The main 
hypothesis is that fatty acids β-oxidation yields a great amount of reducing cofactors (NADH and 
FADH2) and acetyl-CoA, whose carbons are diverted to a limited number of anaplerotic reactions in 
neuron precursors. Instead, glucose and glutamine metabolism are more flexible and dynamic. 
Specifically, glucose can be oxidized in the glycolysis or diverted to pentose phosphate pathway. 
Then, at the end of the glycolysis, pyruvate replenishes: i) cytoplasmic lactate for NAD+ recycling; 
ii) TCA cycle; iii) lipid synthesis and iv) cytoplasmic alanine levels and aspartate in both 
mitochondria and cytosol. Glutamine is converted to glutamate by cytosolic glutaminase-catalyzed 
deamination. In turn, glutamate is converted to αKG in the cytoplasm by glutamic-oxaloacetic 
transaminase 1 (Got1) to feed glutamine reductive pathway for lipid and aspartate synthesis. Got2 
catalyzes the same transamination in the mitochondria to fuel TCA cycle (oxidative pathway) 
[8,24,25]. Aspartate, glutamine and glutamate directly sustain cell proliferation, being a source of 
nitrogen and carbon for nucleotide biosynthesis, but also cell differentiation, being important 
precursors for microtubule and synapse formation, as well as neurotransmitter biosynthesis [26,27]. 
Recent findings also prove that proper cell nutrients catabolism through TCA cycle and ETC are 
instrumental to sustain aspartate production, and hence cell growth [28–32]. Nonetheless, aspartate 
together with acetyl-CoA forms N-acetylaspartate (NAA). NAA is fundamental for axon formation 
and mechanical support by functioning as acetyl groups donor to oligodendrocytes for lipid and 
myelin synthesis [33]. Hence, being pleiotropic metabolic alternatives, glucose and glutamine are 
preferred by mature neurons to support their metabolic requirements. 
 To sustain the metabolic rewiring during neuron maturation, mitochondria meet cellular 
demand by changing their dynamics and shape, thus triggering a bidirectional transcriptional program 
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that suppresses self-renewal, promotes differentiation, and leads to greater mitochondrial 
functionality during neurogenesis [34]. As a proof of this notion, perturbation of mitochondrial 
function in quiescent radial glia-like neural stem cells due to depletion of mitochondrial transcription 
factor A (Tfam) reproduces multiple hallmarks of aging in hippocampal neurogenesis [35]. In 
addition, other evidences elucidated the metabolic changes between quiescent and proliferative NSCs 
[10], or in the transition from NSCs to NPCs [7,9,11]. On the other hand, to date only few reports 
have addressed the role of mitochondria during the maturation process from neuroblasts to neurons 
[36–41], thus a detailed metabolic characterization of this transition is still incomplete. 
 Here, we develop a model of N2a cells with dysfunctional mitochondria to investigate the 
contribution of mitochondria and energy metabolism to the maturation from neuroblast to neuron. 
Specifically, cells were treated with EtBr to interfere with mtDNA biology in a gene-independent 
fashion. Indeed, EtBr-treated N2a cells show increased mtDNA amount but reduced mtDNA 
transcription, leading to impaired Oxphos function and efficiency compared to wild type N2a. 
Notably, EtBr-treated N2a show altered differentiation compared to wild type control due to less and 
shorter neurites, all of which result in a compromised cellular network formation. Conversely, the 
growth rate of Oxphos deficient N2a neuroblasts is unaffected, suggesting the strong ability of these 
cells to rewire their metabolism to sustain cell proliferation at the expense of differentiation.  
Based on these findings, we focused our attention on the metabolic adaptation of EtBr-treated 
cells at neuroblast stage. Combining cell growth analyses, steady state metabolomics and metabolic 
flux analyses, we uncover the biochemical mechanisms underlying cell proliferation and 
differentiation of neuroblasts with Oxphos deficiency, highlighting the robust relationship between 
mitochondrial function, metabolic profile and cell development. Steady state metabolomics reveals 
increased levels of several acylcarnitines, reduced levels of glutamine, glutamate, aspartate and 
glycolysis intermediates in dysfunctional mitochondria N2a neuroblasts. Beyond this, flux analysis 
reveals: i) decreased TCA cycle flux, ii) lower incorporation of glucose and glutamine-derived 
carbons into amino acids from anaplerotic reactions, iii) increased abundance of palmitate-derived 
carbons into amino acids to replenish anaplerotic reactions, and iv) increased transamination of 
glucose-derived pyruvate into alanine, all of which indicate a reduced activity of Idh3. Consistently 
with reduced TCA cycle and ETC activity, we also observe increased ROS levels in Oxphos deficient 
cells only when forced to use β-oxidation by the exposure to palmitate and carnitine. 
Altogether, our data demonstrate that during maturation from neuroblast to neuron, 
mitochondrial function and energy metabolism are not merely settled by nuclear transcription, instead 
they are interconnected and active players in the differentiation process. Moreover, we proved that 
19 
 
fatty acid β-oxidation is a biochemical brake of cell cycle exit, a key process required for neuroblasts 
maturation to neurons (Fig.7).  
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Figure legends 
Fig. 1 Neuroblast N2a model of dysfunctional mitochondrial. a Relative mtDNA amount and mtDNA 
transcription levels (**p<0.01; Student’s t-test vs Wild type, n = 5). b Western blot of Oxphos 
subunits Uqcrc2, mt-COI, Sdhb and Ndufb8 and Hsp90 as loading control. c Basal, uncoupled and 
maximal uncoupled respiration and d complex I, II and IV activities (*p<0.05; **p<0.01; 
***p<0.001; Student’s t-test vs Wild type, n = 5). e Relative ROS levels (n = 8). f Cell proliferation 
based on relative DAPI intensity (to day 0) of N2a cells grown in 4.5g/L galactose, 2mM glutamine 
and 10% FBS (Area Under Curve (AUC), ***p<0.001; Student’s t-test vs Wild type, n = 8). Dashed 
line represents Wild type and EtBr cells grown in complete media. g Proliferation rate of N2a 
neuroblasts (n = 6). Black bars/lines = Wild type N2a; red bars/lines = EtBr-treated N2a. Data are 
expressed as mean ± SD. 
 
Fig. 2 EtBr treatment affects N2a differentiation. a Representative brightfield images of 3 days 
differentiated wild type and EtBr-treated N2a after fixation and blue Coomassie staining (scale bar = 
50μm). b Neurite number, length and contacts quantification (*p<0.05; **p<0.01; ***p<0.001; 
Student’s t-test vs Wild type, n = 5). c Tubb3 mRNA expression levels (*p<0.05; Student’s t-test vs 
Wild type, n = 4). d Tuj1 western blot and relative quantification. Hsp90 represent loading control 
(*p<0.05; Student’s t-test vs Wild type, n = 3). Black bars = Wild type N2a; red bars = EtBr-treated 
N2a. e Basal, uncoupled and maximal uncoupled respiration, and complex I, II and IV activities after 
3 days of differentiation (*p<0.05; **p<0.01; ***p<0.001; Student’s t-test vs Wild type, n = 3). f 
Representative western blot of Oxphos subunits Atp5a1, Uqcrc2, mt-COI, Sdhb and Ndufb8 and 
Hsp90 as loading control. g Western blot (f) quantification (*p<0.05; Student’s t-test vs Wild type, n 
= 3). Data are expressed as mean ± SD. 
 
Fig. 3 Steady-state metabolomic analysis of wild type and dysfunctional mitochondria neuroblasts. a 
Z-score-based heatmap and dendrogram of 58 detected metabolites. b Box plots of significantly 
decreased and c increased metabolites. 
Gray boxes = Wild type N2a; Red boxes = EtBr-treated N2a. Data are expressed as mean ± SD. (False 
Discovery Rate (FDR) < 0.1, Fold Change > 1.5; *p<0.05; **p<0.01; ***p<0.001; Student’s t-test vs 
Wild type, n = 4). 
 
Fig. 4 Fatty acid β-oxidation favors EtBr-treated cells proliferation. a Proliferation rate of Wild type 
and EtBr neuroblasts treated with vehicle or Block of Lipid Transport-1 (BLT-1) 5μM for 48 hours 
(**p<0.01; ***p<0.001; two-way ANOVA followed by Sidak’s multiple comparison test, n = 8). b 
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Relative cell viability (to Wild type with FBS) of Wild type and EtBr neuroblasts treated with 
palmitate at the indicated concentrations for 48 hours in the absence and c presence of 1mM carnitine 
(**p<0.01; ***p<0.001; Student’s t-test vs Wild type, n = 8). d Relative ROS levels of N2a 
neuroblasts grown with 1mM carnitine and 100μM palmitate for 24 hours (***p<0.001; Student’s t-
test vs Wild type, n = 8). e Relative cell viability (to Wild type with vehicle) of Wild type and EtBr 
neuroblasts treated with vehicle or 100μM etomoxir for 24 hours (**p<0.01; Student’s t-test vs Wild 
type, n = 8). Black bars/lines = Wild type N2a; red bars/lines = EtBr-treated N2a; purple line = BLT-
1 treatment. Data are expressed as mean ± SD. 
 
Fig. 5 Metabolic flux analysis indicate increased palmitate-derived carbons contribution to TCA cycle 
intermediates. a Mass isotopomer distribution (MID) of [U-13C6]-Glucose derived acetyl-CoA, b 
citrate, c α-ketoglutarate and d oxaloacetate (*p<0.05; **p<0.01; ***p<0.001; Student’s t-test vs 
Wild type, n = 6). e MID of [U-13C5]-Glutamine derived acetyl-CoA, f citrate, g α-ketoglutarate and 
h oxaloacetate (R indicates metabolites originating from glutamine reductive pathway; *p<0.05; 
**p<0.01; ***p<0.001; Student’s t-test vs Wild type, n = 6). i MID of [U-13C16]-Palmitate derived 
acetyl-CoA, j citrate, k α-ketoglutarate and l oxaloacetate (*p<0.05; **p<0.01; ***p<0.001; 
Student’s t-test vs Wild type, n = 6). m Carbon contribution of different labeled substrates to citrate 
in Wild type and EtBr-treated neuroblasts (*p<0.05; **p<0.01; ***p<0.001; Student’s t-test vs Wild 
type, n = 6). n Schematic representation of metabolic pathways obtained by flux analyses in Wild 
type and EtBr-treated neuroblasts. Black bars = Wild type N2a; red, green, blue bars = EtBr-treated 
N2a with [U-13C6]-Glucose, [U-13C5]-Glutamine and [U-13C16]-Palmitate, respectively; Black circles 
under bars represent 13C labeled carbons; Data are expressed as mean ± SD. Carbon positions are 
schematically represented in each panel. 
 
Fig. 6 Palmitate derived carbons flow into aspartate, glutamate and proline. a [U-13C16]-Palmitate 
derived M2 aspartate, glutamate, proline, b glutamine and c M3 glutamine levels (*p<0.05; **p<0.01; 
***p<0.001; Student’s t-test vs Wild type, n = 6). d [U-13C6]-Glucose derived M2 aspartate, e 
glutamate, proline, glutamine and M3 glutamine levels (**p<0.01; ***p<0.001; Student’s t-test vs 
Wild type, n = 6). f [U-13C5]-Glutamine derived M2 and M4 aspartate, g M2, M3 and M5 glutamate, 
h M2 proline, i and M5 glutamine levels (R indicates metabolites originating from glutamine 
reductive pathway; *p<0.05; **p<0.01; ***p<0.001; Student’s t-test vs Wild type, n = 6). j Schematic 
representation of labeled amino acids obtained by flux analyses in Wild type and EtBr-treated 
neuroblasts. Black bars = Wild type N2a; red, green, blue bars = EtBr-treated N2a with [U-13C6]-
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Glucose, [U-13C5]-Glutamine and [U-13C16]-Palmitate, respectively; Data are expressed as mean ± 
SD. 
 
Fig. 7 Schematic representation of the putative biochemical mechanism underlying neuroblast to 
neuron maturation in wild type and dysfunctional mitochondria N2a cells. Chemically induced 
mitochondrial impairment leads to altered metabolic profile, that by promoting fatty acid β-oxidation 
and pyruvate to alanine transamination sustain cell proliferation to the detriment of complete neuron 
maturation. 
 
Supplementary Figure legends 
Supplementary Fig. 1 EtBr treatment decreases neurite formation in N2a differentiated cells. a 
Representative brightfield images of 3 days differentiated wild type and EtBr-treated N2a after 
fixation and blue Coomassie staining (scale bar = 50μm). b Cell proliferation based on DAPI intensity 
of Wild type neuroblasts and 72h differentiated N2a (***p<0.001; Student’s t-test vs Proliferating 
Wild type cells, n = 8). Black bar = Proliferating Wild type N2a; orange bar = Differentiated Wild 
type N2a. Data are expressed as mean ± SD. 
 
Supplementary Fig. 2 EtBr treatment change metabolic profile of N2a neuroblasts. Principal 
Component Analysis (PCA) performed on targeted steady state metabolomics by MetaboAnalyst 
webtool. 
Red circles = Wild type N2a; Green circles = EtBr-treated N2a. Red and green areas represent 95% 
confidence regions. 
 
Supplementary Fig. 3 Carnitine ratios are increased after EtBr treatment. a Acetyl-L-carnitine 
(C2)/free carnitine (C0) ratio to indicate to measure β-oxidation of fatty acids. b Hexadecanoyl-L-
carnitine (C16:0) + Octadecanoyl-L-carnitine (C18:0)/free carnitine (C0) ratio as measure of the 
activity of Cpt1a, the rate-limiting step in the uptake of fatty acids into mitochondria. Gray boxes = 
Wild type N2a; Red boxes = EtBr-treated N2a. Data are expressed as mean ± SD. (False Discovery 
Rate (FDR) < 0.1, Fold Change > 1.5; **p<0.01; Student’s t-test vs Wild type, n = 4). 
 
Supplementary Fig. 4 Glucose carbons converge to alanine. a [U-13C6]-Glucose derived M2 alanine 
(*p<0.05; Student’s t-test vs Wild type, n = 6), b serine, arginine and glycine. c [U-13C5]-Glutamine 
derived M2 arginine and glycine. d [U-13C16]-Palmitate derived M2 arginine and glycine. Black bars 
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= Wild type N2a; red, green, blue bars = EtBr-treated N2a with [U-13C6]-Glucose, [U-13C5]-
Glutamine and [U-13C16]-Palmitate, respectively; Data are expressed as mean ± SD.  
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